Home/Pipeline/Onvansertib + PARP Inhibitors

Onvansertib + PARP Inhibitors

Ovarian Cancer

PreclinicalDevelopment

Key Facts

Indication

Ovarian Cancer

Phase

Preclinical

Status

Development

Company

Cardiff Oncology

About Cardiff Oncology

Cardiff Oncology's mission is to develop novel cancer therapies by leveraging Polo-like kinase 1 (PLK1) inhibition. Its core achievement is advancing its lead asset, onvansertib, into multiple mid-stage clinical trials in combination with standard regimens for difficult-to-treat cancers like metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC). The company's strategy is predicated on using onvansertib to target tumor vulnerabilities and overcome resistance to existing therapies, aiming to deliver superior clinical benefit. Cardiff's future is entirely tied to the clinical validation of this combination approach.

View full company profile

Therapeutic Areas

Oncology

Other Ovarian Cancer Drugs

Drug	Company	Phase	Status
EXO‑Ovarian Cancer Test	INOVIQ	Phase 2/3	Active
CAR‑iNK‑OvCa	Cartherics	Preclinical	Active
MagSense™ FR Imaging Agent	Imagion Biosystems	Pre‑clinical	Active
Yondelis (trabectedin)	PharmaMar	Approved	Commercial/Lifecycle
Measovir®-based candidate	Oncovita	Pre-clinical	Preclinical activity demonstrated
NP-G2-044 + Chemotherapy Agents	Novita Pharmaceuticals	Phase 2a	Active (combination strategy)
Ivospemin (SBP-101)	Panbela Therapeutics	Phase 2	Active
Ovarian Cancer Early Detection Assay	GenEndeavor	Pre-clinical	Active
INVAC-1	Invectys	Phase 2	Active
Folate Receptor-Targeted PCC	Indi Molecular	Preclinical	Active
Immunomodulator Platform	OmniCyte	Pre-clinical	Active
Platform Candidate	FLAG Therapeutics	Preclinical	Active